Department of Ophthalmology, Eye and Glaucoma Care, Vivekananda Institute of Medical Sciences (VIMS) , Kolkata, India .
J Ocul Pharmacol Ther. 2018 Jul/Aug;34(6):442-451. doi: 10.1089/jop.2017.0135. Epub 2018 May 15.
To evaluate the association of socioeconomic status (SES) with severity of glaucoma and assess the impacts of both SES and disease-severity factors on the costs of glaucoma medications among different glaucoma subtypes in West Bengal, India.
This cross-sectional study (2014-16) followed the treatment of 304 primary glaucoma patients for at least 18 months. The visual field based glaucoma staging was followed for stages 0-3; patients with field of vision <10° were categorized as stage 4 (end stage). We checked only the mean cost of glaucoma medications per patient and not "direct costs." The individuals' monthly incomes were classified into: low, moderate, and higher SES.
Urban residence (odds ratio [OR] 0.6, P < 0.009), higher SES (OR 0.3, P < 0.001), and higher awareness (nearly 50%, P < 0.007) significantly lowered the odds of having end-stage glaucoma. Sixty-nine percent primary angle-closure glaucoma (PACG) and 79% juvenile open-angle glaucoma (JOAG) belonged to low SES, forming the bulk of end-stage glaucoma. Overall medical cost from stage 0 to advanced stage in all subtypes rises except in primary open-angle glaucoma (POAG). Only 28% eyes from low SES were treated with branded drugs in early disease and that too declined to 16% in stage 4, while 57% higher SES used branded medications in early disease stage. Expenditure as a percent of income was the highest in JOAG (16%) followed by PACG (15%) and POAG (14%) among low SES.
Results indicate SES influences on disease outcome, the clinical management, and the glaucoma medication expenses in West Bengal. Medical costs of glaucoma increase with worsening disease severity; greater use of generic drugs does not always ensure direct cost savings.
评估社会经济地位(SES)与青光眼严重程度的关联,并评估 SES 和疾病严重程度因素对印度西孟加拉邦不同青光眼亚型的青光眼药物治疗费用的影响。
这是一项横断面研究(2014-16 年),对至少 18 个月接受原发性青光眼治疗的 304 名患者进行了随访。根据视野对青光眼分期进行了分级,从 0 期到 3 期;视野<10°的患者被归类为 4 期(终末期)。我们只检查了每位患者的青光眼药物平均费用,而不是“直接费用”。将个人月收入分为:低、中、高 SES。
城市居住(比值比 [OR] 0.6,P<0.009)、高 SES(OR 0.3,P<0.001)和高意识(近 50%,P<0.007)显著降低了终末期青光眼的发病几率。69%的原发性闭角型青光眼(PACG)和 79%的青少年开角型青光眼(JOAG)属于低 SES,是终末期青光眼的主要构成部分。除原发性开角型青光眼(POAG)外,所有亚型从 0 期到晚期的总体医疗费用都在增加。只有 28%的低 SES 患者在疾病早期使用了品牌药物,在 4 期时降至 16%,而 57%的高 SES 患者在疾病早期使用了品牌药物。在低 SES 人群中,JOAG(16%)的支出占收入的比例最高,其次是 PACG(15%)和 POAG(14%)。
结果表明 SES 对疾病结局、临床管理和西孟加拉邦的青光眼药物治疗费用有影响。随着疾病严重程度的恶化,青光眼的医疗费用会增加;更多地使用仿制药并不一定能确保直接成本的节约。